Author

A. Ramaiah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 5 Assay:bulk RNA-seq· 2 Research Focus:gene regulatory network inference· 2 Approach:biophysical modeling· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

V. Arumugaswami· 6 shared G. Garcia· 4 shared A. Deb· 2 shared A. Shah· 2 shared A. V. Jeyachandran· 2 shared B. Gomperts· 2 shared C. Sen· 2 shared J. I. Irudayam· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

V. Arumugaswami

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Comparative Analysis of Molecular Pathogenic Mechanisms and Antiviral Development Targeting Old and New World Hantaviruses

A. V. Jeyachandran, J. I. Irudayam, S. Dubey, N. Chakravarty, B. Konda, A. Shah, B. Su, C. Wang, Q. Cui, K. J. Williams, S. Srikanth, Y. Shi, A. Deb, R. Damoiseaux, B. Stripp, , V. Arumugaswami

This study compares molecular mechanisms and antiviral targets of Old and New World hantaviruses using human cell models and identifies potential therapeutic compounds.

bioRxiv · Aug 4, 2023 · PreprintMicrobiology

Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses

G. Garcia, J. Ignatius Irudayam, A. Vijay Jeyachandran, S. Dubey, C. Chang, S. Castillo Cario, N. Price, S. Arumugam, A. L. Marquez, A. Shah, A. Fanaei, N. Chakravarty, S. Joshi, S. Sinha, S. W. French, , V. Arumugaswami

This study identifies broad-spectrum antiviral agents effective against multiple RNA virus families, including arboviruses and respiratory pathogens.

bioRxiv · Jan 19, 2023Microbiology

Hippo Signaling Pathway Activation during SARS-CoV-2 Infection Contributes to Host Antiviral Response

G. Garcia, Y. Wang, J. I. Irudayam, A. V. Jeyachandran, S. C. Cario, C. Sen, S. Li, Y. Li, A. Kumar, K. Nielsen-Saines, S. W. French, P. S. Shah, K. Morizono, B. Gomperts, A. Deb, , V. Arumugaswami

This study identifies Hippo signaling pathway activation as an antiviral response to SARS-CoV-2 infection and shows pharmacological targeting of the pathway can reduce virus replication.

bioRxiv · Apr 7, 2022Microbiology

ORAI1 establishes resistance to SARS-CoV-2 infection by regulating tonic type I interferon signaling

B. Wu, A. Ramaiah, G. Garcia, Y. Gwack, V. Arumugaswami, S. Srikanth

This study shows ORAI1 regulates baseline type I interferon signaling, affecting resistance to SARS-CoV-2 infection.

bioRxiv · May 4, 2021 · PreprintMicrobiology

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication

G. Garcia, A. Sharma, A. Ramaiah, C. Sen, D. Kohn, B. Gomperts, C. N. Svendsen, R. D. Damoiseaux, V. Arumugaswami

This study screens kinase inhibitors to identify compounds that block SARS-CoV-2 replication by targeting key cellular signaling pathways.

Cell Reports · Apr 1, 2021Peer-reviewedMicrobiology

Insights into Cross-species Evolution of Novel Human Coronavirus SARS-CoV-2 and Defining Immune Determinants for Vaccine Development

A. Ramaiah, V. Arumugaswami

This study analyzes the evolution of SARS-CoV-2 and identifies immune determinants for vaccine development by examining mutational changes and T-cell epitopes across viral proteins.

bioRxiv · Jan 29, 2020 · PreprintMicrobiology